Cipla-Pioglitazone 15 mg/30 mg TABLETS
PDF Leaflet Revision Date: 21 August 2020
Clinical Summary
Quick overview from the medicine insert
Indication
Adjunctive therapy for Type 2 diabetes management.
Dosage (summary)
Initial: 15-30 mg once daily; max: 45 mg once daily.
Onset of Action / Duration
Onset: 2 hours, Duration: Not specified
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Insulin
- Gemfibrozil
- Rifampicin
- Ketoconazole
- Midazolam
Contraindications
- Hypersensitivity to pioglitazone
- Impaired liver function
- Cardiac failure
- Pregnancy
- Type 1 diabetes
- Diabetic ketoacidosis
Common side effects
- Weight gain
- Hypoglycaemia
- Congestive heart failure
- Oedema
- Visual disturbances
Counselling Points
- Monitor for signs of heart failure
- Adhere to a calorie-controlled diet
- Use contraception if ovulating
Serious warnings
- Increased risk of bladder cancer
- Monitor liver function
- Risk of heart failure with insulin
Important Disclaimer
The Cipla-Pioglitazone 15 mg/30 mg TABLETS professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
